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ABSTRACT
Background: Nutritional prebiotic supplementation represents an attractive approach for interventions of al-
lergy. In this study, the potential therapeutic effect of β-1, 4 mannobiose (MNB) in a murine model of cedar polli-
nosis was investigated.
Methods: Groups of Balbc mice were intranasally sensitized to Japanese cedar pollen extract, and subse-
quently administered with low or high dose MNB. Both intraperitoneal and intranasal challenges were per-
formed to monitor for clinical signs. Frequency of sneezing was recorded. Serum, spleen and Peyer’s patches
were collected for various biomarker analyses. Anti-allergic activity of MNB using RBL-2H3 cells was also
evaluated.
Results: Significant decrease in sneezing frequency, histamine, interleukin (IL)-4 and IL-17A and increase in
TGF-β and IL-10 concentration were exhibited by the MNB-treated mice. However, Cry j1 and Cry j 2-specific
IgE activity remained unaltered. The high dose MNB treatment increased total IgA activity and IL-10, TGF-β
and FoxP3 and decreased IL-4, IL-17A, and RORγT mRNA expression. Inhibition of activation of RBL-2H3
cells was observed via decrease in histamine, intracellular Ca2+ concentration, and FcεRI mRNA expression.
Conclusions: We demonstrated the immunomodulatory effects of MNB and conclude that MNB is a potential
therapeutic molecular nutritional supplement candidate for treatment of pollen allergy.
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Abbreviations
APC, Antigen-Presenting Cells; Cj, Cryptomeria Japonica; CT, Cholera Toxin; ELISA, Enzyme-Linked Immuno-
sorbent Assay; FOXP3, Forkhead Box Protein 3; IFN-γ, Interferon γ; Ig, Immunoglobulin; IL, Interleukin; MALT,
Mucosa-Associated Lymphoid Tissue; MNB, β-1, 4 mannobiose; PBS, Phosphate Buffered Saline; RORγT,
Retinoic Acid-Related Orphan Receptor; RT-PCR, Reverse-Transcription Polymerase Chain Reaction; TGF,
Transforming-Growth Factor; Th, T Helper Cell; TLR, Toll Like Receptor; Treg, T Regulatory Cell.
INTRODUCTION
Pollinosis caused by Japanese cedar (Cryptomeria ja-
ponica, Cj) pollen is a typical type 1 allergy in Japan
that is prevalent in 10-20% of the population and poses
a major public health problem.1 Clinical signs of Cj
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pollinosis in human subjects are characterized by
sneezing, watery rhinorrhea, and conjunctivitis.2 The
proteins Cry j 1 and Cry j 2 have been isolated and
have been confirmed as the two dominant allergens
associated with Cj pollen allergy.3 Among 145 pa-
tients tested in one study, more than 90% had specific
IgE antibodies to both allergens and the remainder
had specific IgE to either one or the other4 and pa-
tients had T cell reactivity to both Cry j 1 and Cry j 2
tested in another study.5 Although many people suf-
fer from Cj pollinosis, an effective and possible ther-
apy to attenuate and cure the disease has not been es-
tablished yet. Anti-histamine, steroid drug, and anti-
IgE antibody therapies have been widely used to sup-
press the allergic signs, however these treatments ex-
hibit serious side effects.6
Several therapeutic approaches for reducing polli-
nosis using mice as a model have been conducted
earlier.7 Coadministration of cedar pollen allergens
and oligonucleotides led to a type-1 shift in immune
response and inhibited IgE antibody production, sug-
gesting that co-administration strategy may provide a
novel type of immunotherapeutic strategy for cedar
pollinosis.8 It was demonstrated that intramuscular
injections with major Cj pollen allergens effectively
elicits Cry j 1-specific T helper 1 (Th1)-type immune
responses, resulting in inhibition of IgE response to
Cry j 1.9 Also, it was recently demonstrated that Cry j
1-CpG immunization can induce Cry j 1-specific Th1
immune responses, thereby inhibiting IgE response
to the pollen allergen.10 Administration of oligoman-
nose-coated liposomes has been shown to be useful
in immunotherapeutic control of allergic reactions to
Japanese cedar pollinosis in Balbc mice.11 These
studies use various intervention approaches, however
a safe oral intervention to develop an effective and
practical immunotherapeutic approach without any
side effects to treat and prevent Cj pollinosis is lack-
ing. Hence, we hypothesize oral prebiotic therapy as
one such intervention in the management of pollen al-
lergy.
Dietary interventions with nondigestible prebiotic
carbohydrates have been earlier shown to reduce
subsequent frequency to allergic reactions.12-15 The
concept intrigued researchers to develop novel prebi-
otics as a new potential immunotherapeutic approach
to treat and prevent allergy. Several major prebiotics,
including oligofructose, inulin, galactooligosaccha-
rides, and fructooligosaccharides, have been widely
used to stimulate the growth of particular bacterial
species and as an attempt to improve host health.16 It
was also recently shown that the oligosaccharide mix-
ture suppressed cow milk allergy in mice via induc-
tion of regulatory T (Treg) cells.14 However, the
beneficial effect of prebiotics in suppression of aller-
gic response has not been widely investigated.
The β-1, 4 mannobiose (MNB) is considered as a
rare sugar in nature and its biological functions are
not revealed. However, its unique structural feature
and non-metabolic form are expected to have various
immunological functions such as toll like receptor
ligand, innate immunity and such small molecular
(M.W. 342) can cross via intestinal epithelial cells.17
We previously observed that chickens fed MNB had
increased IgA production and improved Salmonella
enteritidis clearance,18 as well as MNB up-regulated
local expression of genes related to host defence and
innate immunity.19,20 These results suggest that
MNB may serve as a potential immune-modulating
agent to exert combined effects on the intestinal im-
mune system. The immune-modulating functions of
MNB naturally intrigued us to explore the potential
effect of MNB in the suppression of allergic response.
Several mouse models of intranasally-induced Japa-
nese cedar pollen allergy have been successfully es-
tablished to investigate the pathogeneses of pollinosis
and evaluate the effects of new therapeutic ap-
proaches.21,22 Also we have recently reported prophy-
laxis of pollen allergic response using MNB in
mice.23 To explore further, in the present study we
have tested the therapeutic effect of MNB in a Balbc
mouse model of intranasally-induced cedar pollinosis
and its potential underlying molecular mechanisms.
Treatment effects were measured as immune re-
sponse phenotypes reflecting type-1 and type-2 re-
lated immune allergic parameters.
METHODS
ANIMALS, MATERIALS, AND REAGENTS
Female Balbc mice (6-7 weeks old) were purchased
from Charles River Laboratories (Montreal, QC, Can-
ada). Pure MNB (of 99% purity) was prepared from
Philippines coconut flour by enzymatic reactions,19,20
and was kindly provided by Fuji Oil (Osaka, Japan).
The structure of MNB was confirmed using C-NMR
and H-NMR (Bruker Bio Sp3 Advance III, 400 MHz
Spectrometer, Tokyo, Japan) (Data not shown). Japa-
nese cedar pollen crude extract and purified pollen al-
lergens (Cry j 1 and Cry j 2) were purchased from
Hayashibara Biochemical Laboratories (Okayama, Ja-
pan). Cholera toxin (CT) was purchased from List Bi-
ologicals Laboratories (Denver, CO, USA). All other
chemicals were purchased from Sigma-Aldrich (St.
Louis, MO, USA).
ANIMAL SENSITIZATION, MNB ADMINISTRA-
TION, AND CHALLENGE PROTOCOLS
As shown in Figure 1, a total of sixty mice were ran-
domly divided into five groups of twelve mice per
group: low dose MNB group; high dose MNB group,
positive control group, negative control group, and
naïve control group. The protocol for sensitization is
well established other researchers.2,24 All animals
were housed in a 12-h lighting cycle and fed a diet
(Harlan Teklad global diet, 14% protein and 3.5% fat,
Madison, WI, USA). Food and water were available
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Fig.　1　Experimental protocol: mouse sensitization, MNB oral administration and fi nal nasal challenge. Alum, 
aluminum hydroxide gel adjuvant; CT, cholera toxin; IP, intraperitoneal; MNB, β-1, 4 mannobiose; PBS, phos-
phate buffered saline.
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ad libitum. All procedures were performed in accor-
dance with the guidelines established by the Cana-
dian Council of Animal Care (CCAC) and approved
by the Animal Care Committee at the University of
Guelph.
Treatment regimen is outlined in Figure 1. Briefly
the positive control group and MNB treatment
groups were intranasally sensitized with 50 μg of
Japanese cedar pollen crude extract, and 1 μg of chol-
era CT in a solution of phosphate buffered saline
(PBS; 25 μL. mouse) twice per week for 6 consecu-
tive weeks. The negative control and naïve control
groups received PBS containing 1 μg of CT and PBS
alone in a similar way. Mice in the low dose MNB
group and high dose MNB group received 85 μg and
340 μg of MNB in 100 μL of PBS solution (oral gav-
age), respectively, three times per week for 6 con-
secutive weeks. The other three groups were orally
gavaged with 100 μL of PBS alone. Mice in the MNB
treated and the positive groups were intraperitoneally
injected once with 100 μL of 50 μg Japanese cedar
pollen crude extract in aluminum hydroxide gel adju-
vant (alum) (2%, Alhydrogel, Westbury, CA, USA).
The negative and naïve control groups were given
100 μL of alum only. All mice were intranasally
treated with 20 ng of histamine dihydrochloride
mouse. One day post histamine pretreatment, mice
were intranasally challenged with 50 μg of Japanese
cedar pollen crude extract in 25 μL of PBS. The fre-
quency of sneezing was measured by sight for 5 min
in an unrestrained whole body plethysmograph post
the last intranasal pollen challenge.24 After the last in-
tranasal antigen challenge, mice were euthuanized
and whole blood and tissue samples were collected.
MEASUREMENT OF HISTAMINE CONCENTRA-
TION
Histamine concentrations in serum and cell culture
supernatants were determined by Enzyme-Linked Im-
munosorbent Assay (ELISA) using a commercial kit
(Histamine EIA, LDN Labor Diagnostika Nord, Nord-
hon, Germany) according to a previously described
procedure.25
DETERMINATION OF ANTIBODY ACTIVITY
Total immunoglobulin (Ig) E and total IgG levels in
the serum were determined by a previously de-
scribed ELISA procedure.26 Pollen specific IgE, IgG,
IgG1 and IgG2a in the serum were determined by a
previously described ELISA procedure with minor
modifications such that the Cry j 1 and Cry j 2 both
were used for coating.25,26 The relative levels of
allergen-specific IgE, IgG, IgG1, and IgG2a in the se-
rum were expressed as optical density (OD).
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ALLERGEN-INDUCED CYTOKINE SECRETION
IN SPLEEN CELL CULTURES
Spleen cells were isolated and stimulated by using a
previously described procedure.26,27 Single cell sus-
pensions of splenocytes were seeded in triplicates
into 96-well flat-bottomed tissue culture plates (Corn-
ing Costar, Fischer Scientific, Pittsburg, USA) (1 ×
106 cellswell) and cultured in the presence of 50 μg
of Cry j 1 and Cry j 2 allergens. Interleukin (IL)-4 and
(interferon) IFN-γ levels were measured by our previ-
ously established ELISA procedures.25 IL-10,
transforming-growth factor (TGF)-β and IL17A were
measured by ELISA with the ELISA Ready-SET-Go!
kit (eBioscience, San Diego, CA, USA) according to
the manufacturer’s protocol.
DETERMINATION OF TOTAL IgA IN FECAL EX-
TRACTS
Mouse fecal pellets were freshly collected on a
weekly basis from each mouse group cage, and were
submitted to a previously described extraction proce-
dure.25 Total IgA levels in fecal extracts were deter-
mined by an ELISA procedure.27
MAST CELL DEGRANULATION ASSAY
Rat basophilic leukemia cells (RBL-2H3; ATCC CRL-
2256) were grown in Eagle’s Minimal Essential Me-
dium (EMEM) (Invitrogen Corp., Grand Island, NY,
USA) supplemented with 1 mM sodium pyruvate (In-
vitrogen), 50 Uml penicillin-streptomycin (Invitro-
gen), and 10% FBS (HyClone, Logan, UT, USA). Cells
were cultured at 37℃ in the presence of 5% CO2, and
medium was replaced every 2-3 days. RBL-2H3 cells
were seeded into 48-well plates (Corning Incorpo-
rated, Corning, NY, USA) at a density of 1 × 105 cells
per well and allowed to adhere for 3 hrs at 37℃ in 5%
CO2. The culture medium was then aspirated and re-
placed with 0.25 ml of fresh medium containing 0.5
μgml of anti-DNP IgE (Clone SPE-7; Sigma-Aldrich)
and incubated overnight 37℃ in 5% CO2. The cells
were then rinsed twice with Tyrode’s buffer (Sigma-
Aldrich) containing 10 mM HEPES and 0.1% BSA,
and pre-incubated in Tyrode’s buffer for 10 min. The
buffer was removed and replaced with 0.25 ml of
DNP-HSA (Sigma-Aldrich) at 100 ngml in Tyrode’s
buffer, and cells were incubated for 1 hr 37℃ in 5%
CO2. Degranulation was assessed by intracellular cal-
cium ion assay and histamine ELISA. In order to as-
sess the effect of MNB on mast cell degranulation,
RBL-2H3 cells were pre-incubated with MNB at 37℃
for 1 h, following sensitization with anti-DNP IgE be-
fore antigenic challenge with DNP-HSA.
MEASUREMENT OF INTRACELLULAR CALCIUM
ION CONCENTRATION
Intracellular Ca2+ concentration was measured using
the fluorescence indicator Fluo-4AM (Molecular
ProbesTM, Invitrogen, Carlsbad, CA, USA). Briefly,
RBL-2H3 cells were seeded into 96 well black opaque
culture plates (PerkinElmer, Waltham, MA, USA) at a
density of 0.5 × 105 cells per well and allowed to ad-
here for 3 hrs at 37℃ in 5% CO2. The culture medium
was then aspirated and replaced with 0.125 ml of
fresh medium containing 0.5 μgml of anti-DNP IgE
and incubated overnight 37℃ in 5% CO2. The cells
were then rinsed twice with Tyrode’s buffer contain-
ing 10 mM HEPES and 0.1% BSA, and pre-incubated
with indicated concentrations of MNB in Tyrode’s
buffer for 1 hr. The buffer was removed and loaded
with Fluo-4 NW dye mix (Molecular ProbesTM, Invi-
trogen) at 37℃ for 45 min. After the removal of Fluo-
4 NW dye mix, cells were challenged for 1 min with
0.125 ml of DNP-HSA at 100 ngml in Tyrode’s
buffer. Intracellular Ca2+ concentration was immedi-
ately detected at a 485-nm excitation wavelength and
a 535-nm emission wavelength at 37℃ with Perkin El-
mer Victor2 TM 1420 Multiple Counter (PerkinEl-
mer).
REAL-TIME RT-PCR ANALYSIS OF GENE EX-
PRESSION IN PEYER’S PATCHES AND RBL.2H3
BASOPHIL CELLS
Peyer’s patches from two mice were pooled within
each group (n = 6 samples per group). Total RNA was
extracted from Peyer’s patches using Aurum total
RNA mini kit (Bio-Rad Laboratories Hercules, CA,
USA). The real-time RT-PCR reactions were per-
formed with qScript cDNA Synthesis kit (Quanta Bi-
oSciences, Gaithersburg, MD, USA) and SYBR
Green I Detection kit (Quanta BioSciences) using an
iCycler iQ Real Time PCR System (Bio-Rad). The se-
quences of the primers used for real-time RT-PCR
analyses are shown in Supplementary Table 1. The
RBL-2H3 cells were analyzed in a similar way for
mRNA expression of FcεRI α, β and γ chain for effect
of MNB and the sequences of the primers used for
real-time RT-PCR analyses are shown in Supplemen-
tary Table 2. The supplementary materials are avail-
able online.
STATISTICAL ANALYSIS
Statistical calculations were performed using the
GraphPad Prism 5.0 package (GraphPad Software,
San Diego, CA, USA). All data were expressed as
means ± SEM and subjected to ANOVA analyses fol-
lowed by post hoc multiple comparison using Tukey’s
test. Comparison of all the endpoint differences with
a level of P < 0.05 was considered significant.
RESULTS
REDUCTION IN SNEEZING FREQUENCY AND
SERUM HISTAMINE RELEASE
Mice that were treated by both dose of MNB had
significantly lower sneezing frequency (P < 0.05)
(Fig. 2a) and serum histamine concentrations (P <
0.05) (Fig. 2b) when compared with mice in the posi-
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Fig.　2　(a) Determination of sneezing frequency in mice during 5 min post 
challenge by pollen allergen at the end point. Data are represented as mean 
± SEM (n = 12 mice per group). (b) Histamine concentration in the serum de-
termined at the end point. Serum samples from two mice were pooled in 
each group and data are represented as mean ± SEM (n = 6). Different as-
terisks indicate statistically signifi cant differences at P < 0.05.
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tive control group. However, there were no differ-
ences (P > 0.05) in the sneezing frequency (Fig. 2a)
and the serum histamine concentrations (Fig. 2b)
among MNB treated groups, negative control and
naïve control groups.
ANTIBODY RESPONSE
As shown in Figure 3a, treatment with low and high
dose of MNB decreased total IgE levels in the serum
(P < 0.05) as compared to those in the positive control
group. However, total IgG levels in the serum did not
differ among MNB treated mice and mice in the posi-
tive control group (P > 0.05) (Fig. 3b). There were no
differences (P > 0.05) in the Cry j 1 and Cry j 2-
specific IgE (Fig. 3c), specific IgG (Fig. 3d), specific
IgG1 (Fig. 3e) and specific IgG2a (Fig. 3f) activity de-
tected in the serum between the MNB treated groups
and the positive control group. Total fecal IgA was
only increased in the high dose MNB group as com-
pared to other groups (Fig. 3g).
CYTOKINE PRODUCTION IN SPLEEN CELL
CULTURE SUPERNATANT
Culture supernatants stimulated in vitro with purified
Cry j 1 and Cry j 2 indicated that IL-4 concentration
was significantly lower (P < 0.05) in the high dose
Yang C et al.
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Fig.　3　Total IgE (a), total IgG (b), pollen allergen (Cry j 1 and Cry j 2)-specifi c IgG (c), IgE (d), 
IgG1 (e), and IgG2a (f) levels in the serum of pollen allergen-sensitized BALB/c mice after repeated 
oral administration of MNB. Serum samples from two mice were pooled within each group. Data are 
represented as mean ± SEM (n = 6). (g) Total IgA levels in fecal extracts of mouse at the end point. 
Data are represented as mean ± SEM (n = 3 replicate tests in fecal extracts). Different asterisks indi-
cate statistically signifi cant differences at P < 0.05.
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MNB-administered group as compared to mice in the
positive control group (Fig. 4a). However, there was
no difference (P > 0.05) in IFN-γ concentration de-
tected among mice in the MNB-administered groups
compared to the positive control group (Fig. 4b).
Mice in the low dose MNB-administered group had
higher IL-10 concentration (P < 0.05) (Fig. 4c) and
TGF-β concentration was significantly higher (P <
0.05) in both the MNB-administered groups as com-
pared to mice in the positive control group (Fig. 4d).
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Fig.　4　Cytokine production of IL-4 (a), IFN-γ (b), IL-10 (c), TGF-β (d), and IL-17A (e) by spleen cells stimulated 
in vitro with pollen allergen (Cry j 1 and Cry j 2). Two spleens from individual mice were pooled within each treat-
ment group (n = 6). Data are represented as mean ± SEM (n = 6). Different asterisks indicate statistically signifi -
cant differences at P < 0.05.
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The IL-17A concentration was significantly lower (P <
0.05) in both the MNB-administered groups (Fig. 4e).
GENE EXPRESSION IN PEYER’S PATCHES
The IL-4 mRNA expression (Fig. 5a) in Peyer’s
patches was lower in both the low and the high dose
MNB group (P < 0.05). The mRNA expression of IL-
10 (Fig. 5b), TGF-β (Fig. 5c) and transcriptional fac-
tor FoxP3 (Fig. 5e) in Peyer’s patches were higher (P
< 0.05) in the high dose MNB group. The mRNA ex-
pression of IL-17A (Fig. 5d) and RORγT (Fig. 5f) in
Peyer’s patches were lower (P < 0.05) in both the low
and high dose MNB groups.
EFFECT OF MNB ON IN VITRO RBL-2H3 ACTIVA-
TION
As shown in Figure 6a, histamine release was signifi-
cantly inhibited (P < 0.05) at all MNB concentrations
when compared to positive control cells (with no
MNB). As shown in Figure 6b, relative to positive
control cells (with no MNB) intracellular Ca2+ level
was significantly lower at 50 μgml (P < 0.05), and
300 μgml (P < 0.05). The mRNA expressions of
FcεRI α chain and γ chain was significantly decreased
(P < 0.05) by MNB at 50 μgml when compared to
negative cells with no MNB (Fig. 6c). However, the
mRNA expression of FcεRI β chain was affected by
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Fig.　5　The mRNA expressions in Peyer’s patches determined by real-time RT-PCR analysis for IL-4 (a), IL-
10 (b), TGF-β (c), IL-17A (d), FoxP3 (e), and RORγT (f). Data are represented as mean ± SEM (n = 6). Differ-
ent asterisks indicate signifi cant differences (P < 0.05).
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MNB addition (P > 0.05).
DISCUSSION
The major purpose of this study was to test the thera-
peutic effects of the nutritional supplement molecule
MNB against Japanese cedar pollen allergy induced
in mice. In this study we have demonstrated allevia-
tion of allergic response in mice via supplementation
of MNB as a molecular food nutritional component
for uses thereof for a hyposensitization therapy,
which may be effective and safe without side effects,
different from the conventional hyposensitization
therapy.
Sneezing frequency is a major clinical sign of hy-
persensitivity to assess the pollen allergy response in
animal models.2,24 In the present study, it was demon-
strated that MNB significantly decreased the sneez-
ing frequency and the serum histamine concentration
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Fig.　6　Effect of β-1, 4 mannobiose (MNB) of RBL-2H3 cell in vitro activation. (a) Following sensitization 
with anti-DNP IgE, RBL-2H3 cells were pre-incubated with MNB at the indicated concentrations for 1 hr at 
37°C, followed by addition of DNP-HSA. Degranulation was measured by histamine ELISA assay. (b) IgE-
sensitized RBL-2H3 cells were loaded with Ca2+ indicator Fluo-4/AM after treatment with indicated concen-
trations of MNB and the cells were stimulated with DNP-HAS for 3 min, and fl uorescence was measured. (c) 
Total RNA was extracted after incubated with MNB at the indicated concentrations for 24 hr at 37°C. The 
IgE receptor mRNA expressionS of RBL-2H3 cells were measured by real-time PCR. Values represent 
mean ± SEM, n = 3. *Different from the negative control cells at P < 0.05.
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and sneezing frequency was positively correlated
with the serum histamine levels (R = squared =
0.4128 and P value = .002), suggesting that MNB ex-
erts therapeutic effects on Japanese cedar pollen al-
lergy.
Type 1 hypersensitivity reactions including Cj polli-
nosis are characterized by allergen-specific IgE as a
vital biomarker,28 however, we found that administra-
tion of MNB did not affect the serum Cry j 1 and Cry j
2-specific IgE concentration, suggesting that the
therapeutic effect of MNB may be due to other regu-
latory mechanisms inducing immune tolerance to pol-
len allergens. Similarly, in earlier studies it was ob-
served that specific immunotherapy did not signifi-
cantly change specific IgE levels post treatment; how-
ever, suppression of allergic response was ob-
served.29,30 Therefore, in this study, measurement of
serum IgE was not a better predictor of allergic clini-
cal signs. A possible explanation for this may be that
quantification of allergen-specific serum IgE may not
reflect allergy-mediating activity of leucocyte FceR1-
bound antibody. This type of tolerance may be in-
duced by several other key mechanisms that include
clonal deletion and induction of tolerogenic Treg cells
that produce IL-10 andor TGF-β.31,32 It was great in-
terest that administration of MNB induced a decrease
in the total serum IgE activity that may also be attrib-
uted to the allergic response. However, the mecha-
nism of decrease in total IgE needs to be further in-
vestigated.
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To clarify the mechanisms involved in the inhibi-
tion of allergy, we examined cytokine production
from splenocytes that were stimulated with Cry j 1
and Cry j 2 in vitro. We found oral administration of
MNB improved type-1type-2 balance of helper T
cells by suppressing IL-4 production (type-1 cytokine)
without changing IFN-γ production (type-2 cytokine)
and induced the Treg cell responses by increasing
TGF-β and IL-10 production, suggesting that MNB
may modulate the balance by inducing Treg cell dif-
ferentiation and alleviating the allergic response. Re-
cently, IL-17A is believed to be involved in the patho-
genesis of allergy diseases and is being discussed as
a potential therapeutic target for allergy.33 Our study
indicated that Th17 cell responses were suppressed
in the spleen by administration of MNB. Although
Th17 responses have been reported to be suppressed
by Treg cell,34 molecular mechanisms behind sup-
pressed Th17 response by MNB administration re-
mains to be elucidated. We found high dose MNB in-
creased the mRNA expression of Treg cell-biased cy-
tokines IL-10 and TGF-β, and transcriptional factor
FoxP3 in peyer’s patches, suggesting that the regula-
tory Foxp3+ T cells is induced by MNB and responsi-
ble for reduction in type-2-cytokine response ob-
served in the spleen and the peyer’s patch. Indeed,
we also found IL-4 mRNA expression was decreased
in Peyer’s patches by administration of MNB. In the
present study, administration of MNB decreased the
mRNA expression of IL17A and the transcriptional
regulator of the Th17 pathway (RORγT) in Peyer’s
patches, suggesting that MNB suppressed Th17 re-
sponse. Although, cytokine production profiles in the
spleen cell culture correlated well with the cytokine
mRNA expression in the Peyer’s patches, the linkage
of systemic immunity and local immunity needs to be
further investigated. Also the relationship between
nasal-associated lymphoid tissue (NALT) and sys-
temic immune response induced by spleen and
Peyer’s patches remains to be further explored.
Secretory IgA, the most abundant antibody isotype
in mucosal immune response, is produced by B cell
and exported by the epithelial polymeric Ig receptor
(pIgR)35 and plays an important role in protecting
against infection in the intestinal immune system,
and its production was previously shown to be in-
creased by dietary MNB in chickens infected with
Salmonella enteritidis.17 Here we found that admini-
stration of high dose MNB induced a similar increase
in total fecal IgA. Recent research showed that high
intestinal IgA played an important role in tolerance
and reduced risk of IgE-associated allergic dis-
eases.36 Moreover, intestinal IgA synthesis is regu-
lated by T-cell dependent and T-cell independent
mechanism and are necessary for intestinal immunity
homeostasis by selecting and maintaining the appro-
priate microbial composition.37 Therefore, the thera-
peutic effect of MNB on allergy may partially be at-
tributed to intestinal IgA secretions.
Our results also supported that Treg cells played
central roles in the MNB-mediated attenuation of pol-
len allergic responses by improving type-1type-2 bal-
ance, suppressing Th17 response and increasing IgA
production. However, whether MNB can interact
with mucosa-associated lymphoid tissue (MALT) as
well as localregional mucosa-draining lymph nodes
through potential receptors or not, such as TLR4, is
still not clear and further investigation is needed. An-
other potential mechanism behind the anti-pollen al-
lergy effect of MNB is that MNB may modulate gut
microbiota which plays a central role in the host in-
nate and adaptive immunity.
In order to further understand the potential anti-
allergy activity mechanisms of MNB, in the present
study we employed the in vitro model of allergic reac-
tion, the rat basophilic leukemia cell line RBL-2H3,
characterized as mucosal mast cells38 to study
whether MNB have the ability to influence mast cell
functionality in vitro. Indeed, we found MNB can in-
hibit histamine release in the mast cells induced by
specific IgE, suggesting that MNB can attenuate the
activation of mast cells. The FcεRI receptor is a key
molecule in triggering IgE-mediated allergic reaction,
and it has been suggested that the downregulation of
its expression in mast cells and basophils may lead to
the attenuation of IgE-mediated allergic symptoms,39
therefore FcεRI and IgE sensitization may be an im-
portant therapeutic target in the treatment of allergy.
Our results indicate that MNB may inhibit mast cell
degranulation through reducing FcεRI mRNA expres-
sion. Calcium influx is essential for FcεRI-mediated
mast cell activation and allergic reaction.40 The ef-
fects of MNB on calcium levels in mast cells were ex-
amined. Our results indicated that MNB can signifi-
cantly reduce intracellular Ca2+ concentration. Take
together, the role of MNB in attenuation of pollen al-
lergic response in mice could be partially due to the
attenuation of activation in the mast cells.
The prophylactic study reported earlier23 signifi-
cantly attenuated pollen allergic response using MNB
by improving Th1Th2 balance, increasing regula-
tory T cell response, decreasing Th17 response, and
increasing IgA production. The present therapeutic
study provides further evidence for role of MNB in at-
tenuation of pollen allergic response in mice by in-
ducing immune tolerance through several ways that
includes a Th2- to a Th1-skewed response, a regula-
tory response involving the transcription factor
FOXP3, induction of regulatory cytokines TGF-β and
IL-10, a suppressed Th17 response, enhanced immu-
noglobulin isotype IgA production, and influencing
mast cell functionality. This may suggest that MNB
may be a potentially useful candidate both prophylac-
tically and therapeutically for the design of a func-
tional prebiotic food component in targeting manage-
ment of Cj pollinosis.
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